{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:08:37Z","timestamp":1791947317827,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4001905"],"award-info":[{"award-number":["4001905"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.MUMS.MEDICAL.REC.1401.101"],"award-info":[{"award-number":["IR.MUMS.MEDICAL.REC.1401.101"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.cyto.2023.156406","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T16:49:20Z","timestamp":1698079760000},"page":"156406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Topical anti-TNF-a ssDNA aptamer decreased the imiquimod induced psoriatic inflammation in BALB\/c mice"],"prefix":"10.1016","volume":"172","author":[{"given":"Saeideh Sadat","family":"Shobeiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Dashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safoora","family":"Pordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MohammadAli","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navideh","family":"Haghnavaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Sankian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2023.156406_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106215","article-title":"Bruton\u2019s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23\/IL-17A in innate immune cells","volume":"80","author":"Nadeem","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"9997","key":"10.1016\/j.cyto.2023.156406_b0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"issue":"9583","key":"10.1016\/j.cyto.2023.156406_b0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cyto.2023.156406_b0020","first-page":"79","article-title":"A brief summary of clinical types of psoriasis","volume":"3","author":"Sarac","year":"2016","journal-title":"North Clin Istanb"},{"key":"10.1016\/j.cyto.2023.156406_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173088","article-title":"Therapeutic treatment with Ibrutinib attenuates imiquimod-induced psoriasis-like inflammation in mice through downregulation of oxidative and inflammatory mediators in neutrophils and dendritic cells","volume":"877","author":"Al-Harbi","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cyto.2023.156406_b0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bcp.2016.10.012","article-title":"Psoriatic inflammation enhances allergic airway inflammation through IL-23\/STAT3 signaling in a murine model","volume":"124","author":"Nadeem","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156406_b0035","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2133.2005.06645.x","article-title":"Psoriasis: dysregulation of innate immunity","volume":"152","author":"Bos","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.cyto.2023.156406_b0040","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3389\/fimmu.2019.01764","article-title":"Adaptive and innate immunity in psoriasis and other inflammatory disorders","volume":"10","author":"Sch\u00f6n","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156406_b0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1590\/S0365-05962012000500001","article-title":"Tumor necrosis factor-alpha and the cytokine network in psoriasis","volume":"87","author":"Brotas","year":"2012","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.cyto.2023.156406_b0050","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/biomedicines10020498","article-title":"Orchestrated cytokines mediated by biologics in psoriasis and its mechanisms of action","volume":"10","author":"Mohd Noor","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cyto.2023.156406_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. paradoxical. the yin-yang of TNF and type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156406_b0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2023.156406_b0065","first-page":"d1356","article-title":"S100 proteins: structure, functions and pathology","volume":"7","author":"Heizmann","year":"2002","journal-title":"Front Biosci"},{"issue":"7","key":"10.1016\/j.cyto.2023.156406_b0070","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/jdv.13269","article-title":"Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity","volume":"30","author":"Wilsmann-Theis","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156406_b0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/bjd.12654","article-title":"Antidrug antibodies in psoriasis: a systematic review","volume":"170","author":"Hsu","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156406_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"J. Dermatolog. Treat."},{"issue":"3","key":"10.1016\/j.cyto.2023.156406_b0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5114\/ada.2018.76086","article-title":"Quo vadis, biological treatment for psoriasis and psoriatic arthritis?","volume":"35","author":"Olszewska","year":"2018","journal-title":"Advances in Dermatology and Allergology\/Post\u0119py Dermatologii i Alergologii"},{"issue":"1","key":"10.1016\/j.cyto.2023.156406_b0090","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","article-title":"Anti-TNF\u03b1 therapy of rheumatoid arthritis: what have we learned?","volume":"19","author":"Feldmann","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2023.156406_b0095","doi-asserted-by":"crossref","first-page":"e2969","DOI":"10.1002\/btpr.2969","article-title":"Designing a new dimerized anti human TNF-\u03b1 aptamer with blocking activity","volume":"36","author":"Mashayekhi","year":"2020","journal-title":"Biotechnol. Prog."},{"issue":"2","key":"10.1016\/j.cyto.2023.156406_b0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156406_b0105","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and limitations of antibody drug conjugates for cancer","volume":"9","author":"Mckertish","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.cyto.2023.156406_b0110","doi-asserted-by":"crossref","unstructured":"M. Mierau, et al., Assessing remission in clinical practice. 2007.","DOI":"10.1093\/rheumatology\/kem007"},{"issue":"10","key":"10.1016\/j.cyto.2023.156406_b0115","doi-asserted-by":"crossref","first-page":"0076","DOI":"10.1038\/s41570-017-0076","article-title":"Analysis of aptamer discovery and technology","volume":"1","author":"Dunn","year":"2017","journal-title":"Nat. Rev. Chem."},{"issue":"3","key":"10.1016\/j.cyto.2023.156406_b0120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cbpa.2006.03.015","article-title":"Aptamer therapeutics advance","volume":"10","author":"Lee","year":"2006","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156406_b0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/cancers10030080","article-title":"Aptamer therapeutics in cancer: current and future","volume":"10","author":"Morita","year":"2018","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.cyto.2023.156406_b0130","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.ymthe.2021.06.010","article-title":"Aptamers: Cutting edge of cancer therapies","volume":"29","author":"Shigdar","year":"2021","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2023.156406_b0135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/13543784.17.1.43","article-title":"Therapeutic applications of aptamers","volume":"17","author":"Kaur","year":"2008","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.cyto.2023.156406_b0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbrc.2022.11.005","article-title":"Selection and characterization of a new human Interleukin-17A blocking DNA aptamer using protein-SELEX","volume":"637","author":"Shobeiri","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cyto.2023.156406_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108326","article-title":"Plaque-type psoriasis inhibitors","volume":"101","author":"Shobeiri","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.cyto.2023.156406_b0150","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Van Der Fits","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156406_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108963","article-title":"Anti-IL-17A ssDNA aptamer ameliorated psoriasis skin lesions in the imiquimod-induced psoriasis mouse model","volume":"110","author":"Shobeiri","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156406_b0160","doi-asserted-by":"crossref","first-page":"e3191","DOI":"10.1002\/btpr.3191","article-title":"A cross-linked anti-TNF-\u03b1 aptamer for neutralization of TNF-\u03b1-induced cutaneous Shwartzman phenomenon: A simple and novel approach for improving aptamers' affinity and efficiency","volume":"37","author":"Mashayekhi","year":"2021","journal-title":"Biotechnol. Prog."},{"issue":"1","key":"10.1016\/j.cyto.2023.156406_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12865-021-00401-3","article-title":"Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist","volume":"22","author":"Li","year":"2021","journal-title":"BMC Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156406_b0170","doi-asserted-by":"crossref","first-page":"1.9.1","DOI":"10.1002\/0471142735.im0109s01","article-title":"Removal of lymphoid organs","volume":"1","author":"Reeves","year":"1992","journal-title":"Curr. Protocols in Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2023.156406_b0175","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/pharmaceutics12090789","article-title":"Advanced characterization of imiquimod-induced psoriasis-like mouse model","volume":"12","author":"Jabeen","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.cyto.2023.156406_b0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156406_b0185","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156406_b0190","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"issue":"6","key":"10.1016\/j.cyto.2023.156406_b0195","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.cyto.2023.156406_b0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00403-020-02056-3","article-title":"Small molecules under development for psoriasis: on the road to the individualized therapies","volume":"312","author":"Claudia","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cyto.2023.156406_b0205","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.biochi.2020.09.023","article-title":"Inhibition of interleukin-2-inducible T-cell kinase causes reduction in imiquimod-induced psoriasiform inflammation through reduction of Th17 cells and enhancement of Treg cells in mice","volume":"179","author":"Nadeem","year":"2020","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.cyto.2023.156406_b0210","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.7150\/thno.30972","article-title":"A novel TNF-\u03b1-targeting aptamer for TNF-\u03b1-mediated acute lung injury and acute liver failure","volume":"9","author":"Lai","year":"2019","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.cyto.2023.156406_b0215","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jid.2017.07.851","article-title":"RNA aptamer delivery through intact human skin","volume":"138","author":"Lenn","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.cyto.2023.156406_b0220","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.5958\/0974-360X.2020.00621.6","article-title":"Imiquimod-induced psoriasis mice model: a promising tool for psoriasis research?","volume":"13","author":"Badanthadka","year":"2020","journal-title":"Res. J. Pharm. Technol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623002843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623002843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:30:10Z","timestamp":1778581810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623002843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":44,"alternative-id":["S1043466623002843"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156406","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical anti-TNF-a ssDNA aptamer decreased the imiquimod induced psoriatic inflammation in BALB\/c mice","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156406"}}